Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized 12-color flow cytometry: A EuroFlow study

MWC. Verbeek, M. Reiterová, A. Laqua, BS. Rodríguez, L. Sedek, C. Buracchi, M. Buysse, E. Oliveira, R. Engelmann, J. Desterro, AX. De Jong, S. Boettcher, R. Jugooa, S. Barrena, S. Kohlscheen, S. Nierkens, JG. Rodriques, M. Hofmans, G. Gaipa, E....

. 2025 ; 9 (4) : e70125. [pub] 20250413

Status not-indexed Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25014561

Detection of minimal/measurable residual disease (MRD) is a critical prognostic marker in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The EuroFlow Consortium previously developed an 8-color flow cytometric MRD protocol, effective for >98% of BCP-ALL patients treated with chemotherapy. This study aimed to enhance MRD detection, particularly for patients treated with CD19-targeted therapies, by expanding the EuroFlow protocol to a 12-color panel. This new panel incorporates additional B-cell markers and exclusion T/NK-cell markers (CD3 and CD7). Through an evaluation of 237 diagnostic BCP-ALL samples, CD22, CD24, and HLA-DR were selected as additional B-cell gating markers. Two 12-color tubes were technically optimized and clinically validated across 101 patient follow-up samples, demonstrating excellent concordance with molecular MRD levels (R2 = 0.88). The 12-color BCP-ALL MRD tubes were compatible with the previously developed 8-color automated gating and identification (AGI) tool and demonstrated good reproducibility. Our findings indicate that the 12-color panel performs comparably to the 8-color BCP-ALL MRD panel, including both CD19-positive and CD19-negative cases. However, it offers an improved definition of the B-cell lineage, particularly for expert-guided manual data analysis, and provides additional information on the expression of the targetable marker CD22.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25014561
003      
CZ-PrNML
005      
20250905141412.0
007      
ta
008      
250701s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/hem3.70125 $2 doi
035    __
$a (PubMed)40224162
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Verbeek, Martijn W C $u Department of Immunology Laboratory for Medical Immunology, Erasmus MC, University Medical Center Rotterdam Rotterdam The Netherlands $1 https://orcid.org/0000000272405176
245    10
$a Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized 12-color flow cytometry: A EuroFlow study / $c MWC. Verbeek, M. Reiterová, A. Laqua, BS. Rodríguez, L. Sedek, C. Buracchi, M. Buysse, E. Oliveira, R. Engelmann, J. Desterro, AX. De Jong, S. Boettcher, R. Jugooa, S. Barrena, S. Kohlscheen, S. Nierkens, JG. Rodriques, M. Hofmans, G. Gaipa, E. Sobral de Costa, E. Mejstrikova, T. Szczepanski, M. Brüggemann, JJM. van Dongen, A. Orfao, VHJ. van der Velden
520    9_
$a Detection of minimal/measurable residual disease (MRD) is a critical prognostic marker in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The EuroFlow Consortium previously developed an 8-color flow cytometric MRD protocol, effective for >98% of BCP-ALL patients treated with chemotherapy. This study aimed to enhance MRD detection, particularly for patients treated with CD19-targeted therapies, by expanding the EuroFlow protocol to a 12-color panel. This new panel incorporates additional B-cell markers and exclusion T/NK-cell markers (CD3 and CD7). Through an evaluation of 237 diagnostic BCP-ALL samples, CD22, CD24, and HLA-DR were selected as additional B-cell gating markers. Two 12-color tubes were technically optimized and clinically validated across 101 patient follow-up samples, demonstrating excellent concordance with molecular MRD levels (R2 = 0.88). The 12-color BCP-ALL MRD tubes were compatible with the previously developed 8-color automated gating and identification (AGI) tool and demonstrated good reproducibility. Our findings indicate that the 12-color panel performs comparably to the 8-color BCP-ALL MRD panel, including both CD19-positive and CD19-negative cases. However, it offers an improved definition of the B-cell lineage, particularly for expert-guided manual data analysis, and provides additional information on the expression of the targetable marker CD22.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Reiterová, Michaela $u CLIP-Department of Pediatric Hematology and Oncology, Second Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic
700    1_
$a Laqua, Anna $u Department of Hematology University of Schleswig-Holstein, Campus Kiel Kiel Germany
700    1_
$a Rodríguez, Beatriz Soriano $u Translational and Clinical Research Program, Department of Medicine Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS University of Salamanca (USAL) Salamanca Spain $u Institute of Biomedical Research of Salamanca (IBSAL) Salamanca Spain $u Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III Madrid Spain
700    1_
$a Sedek, Lukasz $u Department of Microbiology and Immunology Medical University of Silesia Katowice Poland $u Department of Pediatric Hematology and Oncology Medical University of Silesia Katowice Poland
700    1_
$a Buracchi, Chiara $u Pediatrics, Fondazione IRCCS San Gerardo dei Tintori Monza Italy
700    1_
$a Buysse, Malicorne $u Department of Diagnostic Sciences Ghent University Ghent Belgium $u Department of Laboratory Medicine Ghent University Hospital Ghent Belgium
700    1_
$a Oliveira, Elen $u Faculty of Medicine Pediatrics Institute IPPMG Federal University of Rio de Janeiro Rio de Janeiro Brazil
700    1_
$a Engelmann, Robby $u Clinic III (Hematology, Oncology and Palliative Medicine), Special Hematology Laboratory, Rostock University Medical Center Rostock Germany
700    1_
$a Desterro, Joana $u Instituto Português de Oncologia de Lisboa Francisco Gentil, Rua Prof Lima Basto Lisboa Portugal
700    1_
$a De Jong, Anja X $u Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands
700    1_
$a Boettcher, Sebastian $u Clinic III (Hematology, Oncology and Palliative Medicine), Special Hematology Laboratory, Rostock University Medical Center Rostock Germany
700    1_
$a Jugooa, Romana $u Department of Immunology Laboratory for Medical Immunology, Erasmus MC, University Medical Center Rotterdam Rotterdam The Netherlands
700    1_
$a Barrena, Susana $u Translational and Clinical Research Program, Department of Medicine Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS University of Salamanca (USAL) Salamanca Spain $u Institute of Biomedical Research of Salamanca (IBSAL) Salamanca Spain $u Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III Madrid Spain
700    1_
$a Kohlscheen, Saskia $u Department of Hematology University of Schleswig-Holstein, Campus Kiel Kiel Germany
700    1_
$a Nierkens, Stefan $u Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands
700    1_
$a Rodriques, Joana G $u Instituto Português de Oncologia de Lisboa Francisco Gentil, Rua Prof Lima Basto Lisboa Portugal
700    1_
$a Hofmans, Mattias $u Department of Diagnostic Sciences Ghent University Ghent Belgium $u Department of Laboratory Medicine Ghent University Hospital Ghent Belgium
700    1_
$a Gaipa, Giuseppe $u Pediatrics, Fondazione IRCCS San Gerardo dei Tintori Monza Italy
700    1_
$a Sobral de Costa, Elaine $u Faculty of Medicine Pediatrics Institute IPPMG Federal University of Rio de Janeiro Rio de Janeiro Brazil
700    1_
$a Mejstrikova, Ester $u CLIP-Department of Pediatric Hematology and Oncology, Second Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic
700    1_
$a Szczepanski, Tomasz $u Department of Pediatric Hematology and Oncology Medical University of Silesia Katowice Poland
700    1_
$a Brüggemann, Monika $u Department of Hematology University of Schleswig-Holstein, Campus Kiel Kiel Germany
700    1_
$a van Dongen, Jacques J M $u Translational and Clinical Research Program, Department of Medicine Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS University of Salamanca (USAL) Salamanca Spain $u Institute of Biomedical Research of Salamanca (IBSAL) Salamanca Spain $u Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III Madrid Spain $u Department of Immunology LUMC Leiden The Netherlands
700    1_
$a Orfao, Alberto $u Translational and Clinical Research Program, Department of Medicine Cancer Research Centre (IBMCC, CSIC-USAL), Cytometry Service, NUCLEUS University of Salamanca (USAL) Salamanca Spain $u Institute of Biomedical Research of Salamanca (IBSAL) Salamanca Spain $u Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III Madrid Spain
700    1_
$a van der Velden, Vincent H J $u Department of Immunology Laboratory for Medical Immunology, Erasmus MC, University Medical Center Rotterdam Rotterdam The Netherlands
773    0_
$w MED00201259 $t HemaSphere $x 2572-9241 $g Roč. 9, č. 4 (2025), s. e70125
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40224162 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250701 $b ABA008
991    __
$a 20250905141400 $b ABA008
999    __
$a ok $b bmc $g 2388121 $s 1251681
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 9 $c 4 $d e70125 $e 20250413 $i 2572-9241 $m HemaSphere $n Hemasphere $x MED00201259
LZP    __
$a Pubmed-20250701

Find record

Citation metrics

Archiving options